業績超預期 萬華化學(600309.SH)卻大跌超6%
格隆匯4月12日丨上週五盤後公佈業績的萬華化學(600309.SH)今日大跌,盤中一度跌6.45%報100元,跌破半年線,股價創今年1月初以來新低,半日收跌5.77%報100.73元,最新市值3163億元。公司披露2021年一季度營收313.12億元,同比增104.08%;淨利潤66.21億元,同比增380.82%。另外,有數據顯示,睿遠基金明星基金經理傅鵬博在一季度斥資近10億增持近840萬股萬華化學,新晉成為“化工茅”的第八大流通股東。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.